Dr. Reddy's Laboratories

US · RDY #1451 by market cap Listed 1970

12.27 -0.22 -1.76%

Live - 5344 symbols - heartbeat 218s ago · 2026-10-08 08:11

Pre-market 12.27 0.00%

After-hours 12.27 0.00%

Market cap: 10.22B
P/E (TTM): 29.93
P/B: 2.58
EPS: 0.53
Div yield: 0.69%
52W pos: 23%

Reader sentiment Are you bullish or bearish on RDY?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Financial Health how this is computed

Fair

Altman Z-Score is 2.03, in the 1.8-3.0 "grey zone".
Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Revenue annual, last 8 years

Latest year +3.19% YoY

Margins

Gross margin: 52.77%
Operating margin: 14.92%
Net margin: 12.76%

Key ratios & quality

Altman Z-Score: 2.03

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item	2019	2020	2021	2022	2023	2024	2025	2026
Revenue	153.85B	174.60B	189.72B	214.39B	245.88B	279.16B	325.54B	335.93B
Gross profit	83.43B	94.01B	103.08B	113.84B	139.34B	163.61B	190.43B	177.26B
Selling & admin expenses	48.68B	50.13B	54.65B	62.08B	68.03B	77.20B	93.87B	106.76B
Research & development	15.61B	15.41B	16.54B	17.48B	19.38B	22.87B	27.38B	24.06B
Operating profit	19.83B	32.77B	32.91B	35.92B	59.05B	65.31B	72.01B	50.12B
Pretax profit	22.44B	18.03B	26.41B	32.30B	60.37B	71.87B	76.78B	54.82B
Tax	3.65B	-1.47B	9.18B	8.73B	15.30B	16.19B	19.54B	12.35B
Net profit	18.80B	19.50B	17.24B	23.57B	45.07B	55.68B	57.25B	42.47B
Basic EPS	23	24	21	28	54	67	68	51
Diluted EPS	22.62	23.48	20.73	28.34	54.17	66.80	67.78	51.42

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Revenue	85.28B	85.45B	88.05B	87.27B	75.46B	80.71B
Gross profit	56.56B	48.63B	48.14B	46.81B	43.04B	37.54B
Selling & admin expenses	14.01B	23.18B	26.44B	26.92B	14.47B	26.10B
Research & development	--	6.24B	6.20B	6.15B	--	5.77B
Operating profit	16.20B	16.84B	17.87B	14.33B	829.00M	3.03B
Pretax profit	20.05B	19.05B	18.35B	15.43B	2.00B	5.53B
Tax	4.19B	4.95B	4.08B	3.53B	-216.00M	1.18B
Net profit	15.87B	14.10B	14.27B	11.90B	2.21B	4.35B
Basic EPS	19	17	17	15	3	5
Diluted EPS	19.10	17.02	17.25	14.52	2.65	5.32

Balance sheet

Line item	2019	2020	2021	2022	2023	2024	2025	2026
Total current assets	114.50B	130.37B	148.25B	181.86B	204.25B	248.05B	250.11B	301.98B
Cash & ST investments	24.76B	25.74B	34.57B	44.37B	61.80B	81.47B	57.91B	87.81B
Inventory	33.58B	35.07B	45.41B	50.88B	48.67B	63.55B	71.09B	76.53B
Total assets	225.43B	232.24B	265.49B	292.83B	321.85B	387.52B	492.99B	579.35B
Total current liabilities	59.70B	72.81B	83.39B	94.02B	85.85B	96.04B	130.39B	167.57B
Short-term debt	16.38B	20.80B	24.01B	28.10B	12.19B	14.03B	38.90B	65.14B
Long-term debt	21.45B	--	3.80B	3.80B	--	3.80B	3.80B	--
Total liabilities	85,230,000,000.00	77,253,000,000.00	92,429,000,000.00	102,300,000,000.00	90,863,000,000.00	106,968,000,000.00	155,823,000,000.00	198,889,000,000.00
Total equity	140.20B	154.99B	173.06B	190.53B	230.99B	280.55B	337.17B	380.46B
Retained earnings	128.65B	144.25B	156.02B	175.71B	215.59B	265.26B	315.79B	351.98B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Total current assets	250.11B	269.90B	279.52B	297.55B	301.98B	299.33B
Cash & ST investments	57.91B	66.69B	69.81B	82.59B	87.81B	81.43B
Inventory	71.09B	75.60B	75.82B	79.01B	76.53B	80.47B
Total assets	492.99B	519.54B	542.01B	562.90B	579.35B	575.31B
Total current liabilities	130.39B	142.59B	150.93B	158.31B	167.57B	157.34B
Short-term debt	38.90B	43.55B	46.90B	56.12B	65.14B	60.07B
Long-term debt	3.80B	--	--	--	--	--
Total liabilities	155,823,000,000.00	165,782,000,000.00	179,923,000,000.00	187,143,000,000.00	198,889,000,000.00	188,570,000,000.00
Total equity	337.17B	353.76B	362.08B	375.76B	380.46B	386.74B
Retained earnings	315.79B	329.97B	337.68B	349.78B	351.98B	356.42B

Cash flow

Line item	2019	2020	2021	2022	2023	2024	2025	2026
Operating cash flow	28.70B	29.84B	35.70B	28.11B	58.88B	45.43B	46.43B	56.76B
Depreciation & amortization	12.19B	12.47B	12.80B	11.82B	12.64B	14.84B	17.06B	20.61B
Free cash flow	20.33B	23.73B	23.14B	9.06B	40.01B	18.00B	12.03B	18.33B
Dividends paid	-4.00B	-3.92B	-4.15B	-4.15B	-4.98B	-6.65B	-6.66B	-6.66B
Stock buybacks / issuance	-535.00M	-470.00M	-924.00M	334.00M	368.00M	805.00M	-1.20B	397.00M
Ending cash balance	2.23B	1.96B	14.82B	14.85B	5.78B	7.11B	14.59B	15.37B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Operating cash flow	22.00B	14.63B	15.57B	10.91B	15.65B	-927.00M
Depreciation & amortization	4.55B	4.77B	5.05B	5.21B	5.58B	5.37B
Free cash flow	10.75B	4.48B	5.44B	3.59B	4.82B	-4.63B
Dividends paid	0	0	-6.66B	0	0	0
Stock buybacks / issuance	-8.43B	196.00M	92.00M	30.00M	79.00M	248.00M
Ending cash balance	14.59B	9.00B	9.91B	18.66B	15.37B	11.20B

Returns & efficiency

Line item	2019	2020	2021	2022	2023	2024	2025	2026
ROE %	14.10	13.21	10.51	12.96	21.38	21.77	18.42	12.06
ROA %	8.33	8.52	6.93	8.44	14.66	15.70	12.84	7.99
ROIC %	10.62	11.00	9.11	11.02	19.30	20.27	16.65	10.27
5-year avg ROE %	14.02	12.28	11.04	11.72	14.43	15.97	17.01	17.32
EBIT margin %	15.17	10.89	14.43	15.51	25.13	26.36	24.46	17.43
FCF / sales %	13.79	13.59	12.20	4.23	16.27	6.45	3.70	5.46
Current ratio	1.92	1.79	1.78	1.93	2.38	2.58	1.92	1.80
Quick ratio	1.25	1.20	1.15	1.33	1.69	1.84	1.29	1.26
Debt / assets	17.03	9.52	11.42	11.56	4.19	5.17	9.49	13.35
LT debt / equity	15.69	0.84	3.64	3.02	0.55	2.14	2.36	3.24
Interest coverage	26.25	19.34	28.23	34.71	43.27	43.00	28.14	15.66
Revenue CAGR (3Y) %	-0.19	7.43	10.13	11.70	12.09	13.74	14.94	10.96
Net income CAGR (3Y) %	-2.07	17.44	20.69	7.84	32.22	47.83	33.87	-1.67
FCF CAGR (3Y) %	-8.31	--	49.07	-23.62	19.03	-8.04	9.92	-22.91

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
ROE %	18.42	17.62	17.66	16.40	12.06	9.03
ROA %	12.84	12.15	11.63	10.84	7.99	6.05
ROIC %	16.65	15.69	15.19	13.98	10.27	7.86
5-year avg ROE %	--	--	--	--	--	--
EBIT margin %	24.46	23.95	23.21	22.04	17.43	13.73
FCF / sales %	3.70	4.32	5.40	7.01	5.46	2.78
Current ratio	1.92	1.89	1.85	1.88	1.80	1.90
Quick ratio	1.29	1.28	1.26	1.31	1.26	1.31
Debt / assets	9.49	9.36	10.80	12.03	13.35	12.51
LT debt / equity	2.36	1.46	3.25	3.12	3.24	3.10
Interest coverage	28.14	26.16	24.73	22.84	15.66	10.92
Revenue CAGR (3Y) %	--	--	--	--	--	--
Net income CAGR (3Y) %	--	--	--	--	--	--
FCF CAGR (3Y) %	--	--	--	--	--	--

✦ Quant Revenue Concentration how this is computed

Single-engine

Global Generics is the largest reported line at 89.02% of revenue, across 3 reported segments.
The next-largest line, Pharmaceutical Services and Active Ingredients (PSAI), is a distant second at 10.35% - a sharp slowdown here would have little to offset it.

Revenue breakdown most recent period

Business

Global Generics89.02%

Pharmaceutical Services and Active Ingredients (PSAI)10.35%

Others0.63%

Region

Others35.34%

United States35.09%

India19.21%

Russia10.36%

Quote time 2026-10-08 08:11:49 · For reference only, not investment advice and not tailored to your situation.